276 related articles for article (PubMed ID: 22671931)
1. Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/ µ opioid receptor antagonist.
Wade PR; Palmer JM; McKenney S; Kenigs V; Chevalier K; Moore BA; Mabus JR; Saunders PR; Wallace NH; Schneider CR; Kimball ES; Breslin HJ; He W; Hornby PJ
Br J Pharmacol; 2012 Nov; 167(5):1111-25. PubMed ID: 22671931
[TBL] [Abstract][Full Text] [Related]
2. Mixed MOP/DOP agonist biphalin elicits anti-transit effect in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms.
Zielińska M; Jarmuż A; Sałaga M; Lipkowski AW; Fichna J
Pharmacol Rep; 2016 Feb; 68(1):32-6. PubMed ID: 26721348
[TBL] [Abstract][Full Text] [Related]
3. Methyl-orvinol-Dual activity opioid receptor ligand inhibits gastrointestinal transit and alleviates abdominal pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome.
Zielińska M; Jarmuż A; Wasilewski A; Cami-Kobeci G; Husbands S; Fichna J
Pharmacol Rep; 2017 Apr; 69(2):350-357. PubMed ID: 28187396
[TBL] [Abstract][Full Text] [Related]
4. Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms.
Sobczak M; Cami-Kobeci G; Sałaga M; Husbands SM; Fichna J
Eur J Pharmacol; 2014 Aug; 736():63-9. PubMed ID: 24815321
[TBL] [Abstract][Full Text] [Related]
5. Central and peripheral modulation of gastrointestinal transit in mice by DN-9, a multifunctional opioid/NPFF receptor agonist.
Xu B; Guo Y; Zhang M; Zhang R; Chen D; Zhang Q; Xiao J; Xu K; Li N; Qiu Y; Zhu H; Niu J; Zhang X; Fang Q
Neurogastroenterol Motil; 2020 Aug; 32(8):e13848. PubMed ID: 32281198
[TBL] [Abstract][Full Text] [Related]
6. Effects of methylnaltrexone on guinea pig gastrointestinal motility.
Anselmi L; Huynh J; Vegezzi G; Sternini C
Naunyn Schmiedebergs Arch Pharmacol; 2013 Apr; 386(4):279-86. PubMed ID: 23361094
[TBL] [Abstract][Full Text] [Related]
7. Preclinical studies of opioids and opioid antagonists on gastrointestinal function.
Greenwood-Van Meerveld B; Gardner CJ; Little PJ; Hicks GA; Dehaven-Hudkins DL
Neurogastroenterol Motil; 2004 Oct; 16 Suppl 2():46-53. PubMed ID: 15357851
[TBL] [Abstract][Full Text] [Related]
8. Positive allosteric modulation of endogenous delta opioid receptor signaling in the enteric nervous system is a potential treatment for gastrointestinal motility disorders.
DiCello JJ; Carbone SE; Saito A; Pham V; Szymaszkiewicz A; Gondin AB; Alvi S; Marique K; Shenoy P; Veldhuis NA; Fichna J; Canals M; Christopoulos A; Valant C; Poole DP
Am J Physiol Gastrointest Liver Physiol; 2022 Jan; 322(1):G66-G78. PubMed ID: 34755545
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.
Fujita W; Gomes I; Dove LS; Prohaska D; McIntyre G; Devi LA
Biochem Pharmacol; 2014 Dec; 92(3):448-56. PubMed ID: 25261794
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity to μ-opioid receptor-mediated anti-nociception is determined by cross-regulation between μ- and δ-opioid receptors at supraspinal level.
Ballesta JJ; Cremades J; Rodríguez-Muñoz M; Garzón J; Faura CC
Br J Pharmacol; 2012 May; 166(1):309-26. PubMed ID: 22023056
[TBL] [Abstract][Full Text] [Related]
12. The effect of opioid agonists and antagonists on gastrointestinal motility in mice selected for high and low swim stress-induced analgesia.
Wasilewski A; Lesniak A; Bujalska-Zadrozny M; Sadowski B; Fichna J; Sacharczuk M
Neurogastroenterol Motil; 2016 Feb; 28(2):175-85. PubMed ID: 26510904
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic Profile of Naloxegol, a Peripherally Acting
Floettmann E; Bui K; Sostek M; Payza K; Eldon M
J Pharmacol Exp Ther; 2017 May; 361(2):280-291. PubMed ID: 28336575
[TBL] [Abstract][Full Text] [Related]
14. Central effect of mu-opioid agonists on antral motility in conscious rats.
Tsuchida D; Fukuda H; Koda K; Miyazaki M; Pappas TN; Takahashi T
Brain Res; 2004 Oct; 1024(1-2):244-50. PubMed ID: 15451387
[TBL] [Abstract][Full Text] [Related]
15. Novel orally available salvinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.
Sałaga M; Polepally PR; Sobczak M; Grzywacz D; Kamysz W; Sibaev A; Storr M; Do Rego JC; Zjawiony JK; Fichna J
J Pharmacol Exp Ther; 2014 Jul; 350(1):69-78. PubMed ID: 24891526
[TBL] [Abstract][Full Text] [Related]
16. Intracerebroventricular administration of CYX-6, a potent μ-opioid receptor agonist, a δ- and κ-opioid receptor antagonist and a biased ligand at μ, δ & κ-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine.
Imam MZ; Kuo A; Ghassabian S; Cai Y; Qin Y; Li T; Smith MT
Eur J Pharmacol; 2020 Mar; 871():172918. PubMed ID: 31958457
[TBL] [Abstract][Full Text] [Related]
17. Involvement of mu-opioid receptors in antinociception and inhibition of gastrointestinal transit induced by 7-hydroxymitragynine, isolated from Thai herbal medicine Mitragyna speciosa.
Matsumoto K; Hatori Y; Murayama T; Tashima K; Wongseripipatana S; Misawa K; Kitajima M; Takayama H; Horie S
Eur J Pharmacol; 2006 Nov; 549(1-3):63-70. PubMed ID: 16978601
[TBL] [Abstract][Full Text] [Related]
18. The in vivo pharmacodynamics of the novel opioid receptor antagonist, TD-1211, in models of opioid-induced gastrointestinal and CNS activity.
Armstrong SR; Campbell CB; Richardson CL; Vickery RG; Tsuruda PR; Long DD; Hegde SS; Beattie DT
Naunyn Schmiedebergs Arch Pharmacol; 2013 Jun; 386(6):471-8. PubMed ID: 23512167
[TBL] [Abstract][Full Text] [Related]
19. Novel opioid cyclic tetrapeptides: Trp isomers of CJ-15,208 exhibit distinct opioid receptor agonism and short-acting κ opioid receptor antagonism.
Ross NC; Reilley KJ; Murray TF; Aldrich JV; McLaughlin JP
Br J Pharmacol; 2012 Feb; 165(4b):1097-108. PubMed ID: 21671905
[TBL] [Abstract][Full Text] [Related]
20. Treatment of opioid-induced gut dysfunction.
Holzer P
Expert Opin Investig Drugs; 2007 Feb; 16(2):181-94. PubMed ID: 17243938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
